L. Crinò

Thomas Henzler, Rozemarijn Vliegenthart, Lucio Crino, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer

L. Crinò, P. Floridi, R. Chiari, 2015, Expert opinion on pharmacotherapy.

Perspectives on salvage therapy for non-small-cell lung cancer.

F. Cappuzzo, R. Trisolini, L. Crinò, 2005, Oncology.

Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer

G. Bepler, G. Scagliotti, M. Rinaldi, 2003, Oncogene.

Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer.

L. Crinò, M. Tonato, E. Corgna, 1998, Lung cancer.

Safety of Epirubicin Adjuvant Chemotherapy in a Breast Cancer Patient with Chronic Renal Failure Undergoing Hemodialytic Treatment

L. Crinò, M. Colozza, S. Gori, 2006, Tumori.

Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.

A. Shaw, S. Ou, Gregory Riely, 2012 .

Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?

L. Crinò, G. Metro, V. Minotti, 2012, Journal of thoracic disease.

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting

L. Crinò, A. Delmonte, G. Bronte, 2020, Cancers.

Tasisulam Sodium (LY573636 Sodium) as Third-Line Treatment in Patients With Unresectable, Metastatic Non–Small-Cell Lung Cancer: A Phase-II Study

G. Scagliotti, S. Novello, L. Crinò, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1064 Gemcitabine-cisplatin combination in non-small cell lung cancer (NSCLC). A phase II study

L. Crinò, M. Marangolo, V. Adamo, 1995 .

High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.

L. Crinò, M. Tonato, V. Ludovini, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients

L. Crinò, G. Martinelli, D. Calistri, 2022, Cancers.

Gene identification for risk of relapse in stage I lung adenocarcinoma patients: a combined methodology of gene expression profiling and computational gene network analysis

L. Crinò, R. Chiari, V. Ludovini, 2016, Oncotarget.

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.

P. Jänne, F. Cappuzzo, W. Franklin, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

L. Crinò, S. Ricci, C. Orlandini, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy.

R. Labianca, A. Brandes, C. Gridelli, 2009, Lung Cancer.

Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.

L. Crinò, C. Calandri, A. Maestri, 2001, Oncology.

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. de Ruysscher, D. Ruysscher, S. Peters, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer.

L. Crinò, M. Giansanti, T. Todisco, 1995, Lung cancer.

Long-term results of induction chemotherapy followed by concurrent chemotherapy and thoracic irradiation in limited small cell lung cancer.

F. de Marinis, L. Crinò, M. Tonato, 2002, Lung cancer.

Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation

L. Crinò, R. Chiari, C. Bennati, 2011, Cancer Chemotherapy and Pharmacology.

Phase II study of high-dose paclitaxel and carboplatin in previously untreated, unresectable non-small cell lung cancer.

G. Scagliotti, S. Novello, L. Crinò, 2001, Lung cancer.

Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.

G. Scagliotti, A. Rossi, C. Gridelli, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer.

L. Crinò, M. Tonato, E. Maranzano, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Lung cancer.

L. Crinò, J. Foglietta, A. Hamzaj, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.

G. Rossi, L. Crinò, A. Ardizzoni, 2006, Lung cancer.

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

P. Visca, L. Crinò, V. Ludovini, 2014, Journal of Translational Medicine.

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’

E. Petricoin, P. Valigi, L. Crinò, 2016, BMC Systems Biology.

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

P. Jänne, A. Shaw, L. Crinò, 2012 .

Gefitinib (ZD1839) treatment for adult patients with progressive high-grade gliomas (HGG): An open label, single-arm, phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

A. Brandes, L. Crinò, S. Lonardi, 2005 .

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients

G. Botti, D. Galetta, L. Crinò, 2019, Cancers.

Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.

F. Cappuzzo, F. de Marinis, L. Crinò, 2019, Lung cancer.

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.

N. Pavlakis, Yi-long Wu, L. Crinò, 2010, The Lancet. Oncology.

Targeting RET-rearranged non-small-cell lung cancer: future prospects

L. Crinò, A. Delmonte, P. Ulivi, 2019, Lung Cancer.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

F. Cappuzzo, L. Livi, F. de Marinis, 2018, European journal of cancer.

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)

A. Brandes, L. Crinò, M. Ermani, 2006, British Journal of Cancer.

Recommendations for mutational analysis of EGFR in lung carcinoma.

A. Marchetti, G. Botti, G. Fontanini, 2010, Pathologica.

Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).

A. Shaw, S. Gettinger, S. Ou, 2012 .

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects

F. Cappuzzo, L. Crinò, E. Petracci, 2021, Frontiers in Cell and Developmental Biology.

Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.

L. Crinò, V. Ludovini, G. Servillo, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

A. Brandes, L. Crinò, A. Pession, 2007, British Journal of Cancer.

P-362 Role of mitogen-activated protein kinase (MAPK) and AKT as predictive factors for response to ZD 1839 therapy in non-small cell lung cancer (NSCLC) patients

F. Cappuzzo, A. Cancellieri, L. Crinò, 2003 .

Novel molecular trends in the management of advanced non-small-cell lung cancer

L. Crinò, G. Metro, 2012, Expert review of anticancer therapy.

ERCC1 expression in triple negative breast carcinoma: the paradox revisited

L. Crinò, M. Colozza, S. Gori, 2008, Breast Cancer Research and Treatment.

Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.

R. Labianca, C. Tibaldi, E. Smit, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.

D. Galetta, L. Crinò, G. Colucci, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

O-107 FISH and Immunohistochemistry (IHC) can be used to selectNSCLC patients, who will not benefit from gefitinib treatment

F. Hirsch, P. Bunn, D. Gandara, 2005 .

Clinical and biological effects of gefitinib in EGFR FISH positive/phospho-akt positive or never smoker non-small cell lung cancer (NSCLC): Preliminary results of the ONCOBELL trial.

W. Franklin, R. Trisolini, L. Crinò, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of the National Cancer Institute.

Enteric-type adenocarcinoma of the lung harbouring a novel KRAS Q22K mutation with concomitant KRAS polysomy: a case report

L. Crinò, V. Ludovini, E. Valtorta, 2015, Ecancermedicalscience.

Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma

L. Crinò, A. Pession, S. Rimondini, 2004, British Journal of Cancer.

Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update

L. Crinò, N. Rizvi, M. Hellmann, 2016 .

Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients

S. Barni, A. Brandes, C. Gridelli, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, A. Gazdar, F. Hirsch, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study

L. Crinò, C. Orlandini, A. Santoro, 2005, British Journal of Cancer.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CSF Concentration of Crizotinib in Two ALK-Positive Non-Small-Cell Lung Cancer Patients with CNS Metastases Deriving Clinical Benefit from Treatment.

L. Crinò, P. Floridi, R. Chiari, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

ASCEND-2: A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ).

H. Groen, G. Scagliotti, H. Wakelee, 2015 .

Selumetinib in combination with docetaxel as second-line treatment for patients with KRAS-mutant advanced NSCLC: results from the phase III SELECT-1 trial.

P. Jänne, A. Kohlmann, L. Crinò, 2016 .

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

L. Crinò, C. Boni, M. Clerici, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer

P. Jänne, F. Cappuzzo, W. Franklin, 2007 .

Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.

G. Scagliotti, C. Tibaldi, M. Rinaldi, 2009, Lung cancer.

Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.

L. Crinò, A. Inno, L. Del Mastro, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Vindesine and mitomycin c in chemotherapy refractory advanced breast cancer

L. Crinò, M. Tonato, F. Grignani, 1986, Cancer.

Emerging drugs for small cell lung cancer – an update

F. Cappuzzo, L. Crinò, G. Metro, 2012, Expert opinion on emerging drugs.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).

F. Cappuzzo, C. Gridelli, L. Crinò, 2003, Lung cancer.

HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients

F. Cappuzzo, F. Hirsch, P. Bunn, 2005, British Journal of Cancer.

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

G. Hortobagyi, R. Rizzoli, F. Saad, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study

L. Crinò, V. Ludovini, F. Barberini, 2009, BMC Cancer.

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations

G. Minuti, L. Crinò, M. Canale, 2022, Translational oncology.

31 Differential efficacy and toxicity profiles of 4 different schedules of gemcitabine and cisplatin combination in non-small cell lung cancer (NSCLC)

L. Crinò, Mark R. Green, B. Nguyen, 1997 .

Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma.

L. Crinò, S. Bracarda, M. Porena, 1996, European urology.

HER-2 Inhibitors: Clinical Results

L. Crinò, E. Franceschi, L. Scopece, 2002, I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.].

DKC1 gene mutations in human sporadic cancer.

L. Crinò, L. Montanaro, D. Treré, 2013, Histology and histopathology.

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate 017/057 2-y update and exploratory cytokine profile analyses.

E. Felip, L. Crinò, N. Rizvi, 2016 .

RET rearrangements detected by FISH in "pan-negative" lung adenocarcinoma.

P. Bunn, M. Varella‐Garcia, R. Doebele, 2013 .

Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

L. Landi, L. Crinò, M. Tiseo, 2019, European journal of cancer.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2016, Clinical Drug Investigation.

Acute Myeloblastic Leukemia after Adjuvant Chemotherapy with Melphalan in Breast Cancer. Case Report with Cytogenetic Analysis

L. Crinò, M. Tonato, C. Mecucci, 1983, Tumori.

Pharmacokinetics of Trastuzumab in Haemodialysis

L. Crinò, A. Inno, L. Del Mastro, 2015, The breast journal.

Combination therapy with gemcitabine in non-small cell lung cancer.

L. Crinò, M. Tonato, A. Mosconi, 1997, European journal of cancer.

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis

L. Crinò, M. Canale, E. Petracci, 2022, Frontiers in Immunology.

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

L. Landi, F. Cappuzzo, L. Crinò, 2021, Frontiers in Oncology.

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

A. Drilon, S. Gettinger, L. Crinò, 2019, The Lancet. Oncology.

Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population.

A. Chella, F. Cappuzzo, D. Galetta, 2019, The oncologist.

Reliability and validity of a quality of life questionnaire in cancer patients.

L. Crinò, M. Tonato, M. Soldani, 1993, European journal of cancer.

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY

E. Papini, R. Valcavi, G. Arnaldi, 2012, Journal of Endocrinological Investigation.

Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

E. Felip, L. Crinò, J. V. van Meerbeeck, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors

L. Crinò, M. Canale, A. Delmonte, 2021, Frontiers in Immunology.

Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study

A. Abbruzzese, M. Caraglia, G. Vitale, 2012, Journal of cellular and molecular medicine.

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.

L. Crinò, H. von der Maase, L. Dogliotti, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

G. Scagliotti, F. de Marinis, L. Crinò, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Original article A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial

G. Scagliotti, C. Gridelli, M. Rinaldi, 2005 .

Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).

L. Crinò, C. Boni, F. di Costanzo, 1998, European journal of cancer.

A better therapeutic profile for the combination of mitomycin-C, ifosfamide and cisplatin (MIC) in advanced non-small-cell lung cancer: a useful dose-schedule modification.

L. Crinò, M. Tonato, E. Corgna, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin (CDDP)-etoposide VS DCCP-mitomycin-vindesine VS CDDP-mitomycin-iphosphamide in advanced non small cell lung cancer (NSCLC). A prospective randomized trial of the Italian oncology group for clinical research. (GOIRC)

L. Crinò, C. Boni, M. Clerici, 1993 .

Gemcitabine in advanced pancreatic cancer: a phase II trial.

L. Crinò, M. Tonato, E. Corgna, 2001 .

Chemotherapy in advanced non-small-cell lung cancer. The experience of Italian Cooperative Groups.

L. Crinò, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'.

L. Crinò, S. Gori, G. Metro, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

1315PEfficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in Italy

L. Crinò, F. Roila, A. Delmonte, 2017 .

P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy.

S. Gettinger, L. Crinò, S. Ramalingam, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

L. Crinò, A. Delmonte, G. Bronte, 2022, Cancers.

P3.02c-095 Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non-Small Cell Lung Cancer Patients: Topic: IT Clinical

D. Galetta, L. Crinò, A. Ardizzoni, 2017 .

Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib

F. Hirsch, P. Bunn, W. Franklin, 2006 .

O-271 Phase II randomized study of pemetrexed plus carboplatin or oxaliplatin, as front-line chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer

G. Scagliotti, L. Crinò, C. Kortsik, 2003 .

The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.

L. Crinò, F. Mazzoni, P. Conte, 2001, Oncology.

Neoadjuvant Cisplatin and Etoposide for Stage IIIA (Clinical N2) Non‐Small Cell Lung Cancer

L. Crinò, M. Tonato, E. Maranzano, 1994, American journal of clinical oncology.

Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.

C. Tibaldi, L. Crinò, A. Ardizzoni, 2015, Clinical lung cancer.

M12-04: EGFR/VEGF Inhibitors in combination with other modalities: Zactima (ZD6474) in combination

L. Crinò, S. Gori, 2007 .

A Pilot Study on the Effect of Acetyl-L-Carnitine in Paclitaxel-And Cisplatin-Induced Peripheral Neuropathy

L. Crinò, E. Cortesi, A. Maestri, 2005, Tumori.

Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models

E. Petricoin, L. Crinò, V. Ludovini, 2021, International journal of molecular sciences.

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

A. Shaw, S. Ou, F. de Marinis, 2019, Lung Cancer.

Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma

L. Crinò, A. Delmonte, G. Bronte, 2021, Frontiers in Pharmacology.

Multimodality therapy for non-small cell lung cancer (NSCLC): ongoing Italian experiences in the adjuvant and neoadjuvant settings.

L. Crinò, F. Cappuzzo, 2001, Lung cancer.

Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.

G. Scagliotti, C. Gridelli, M. Rinaldi, 1998, Seminars in oncology.

O-191 HER1-HER2-HER3 gene amplification and akt activation inpatients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib

F. Hirsch, P. Bunn, W. Franklin, 2005 .

Targeting EGFR and ALK in NSCLC: current evidence and future perspective

L. Crinò, C. Bennati, A. Gili, 2016 .

Primary and metastatic brain tumors.

L. Crinò, R. Chiari, S. Gori, 2006, Forum.

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis

L. Crinò, G. Bronte, A. Procopio, 2022, Clinical and Experimental Medicine.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL)

N. Pavlakis, L. Crinò, N. Thatcher, 2008 .

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

L. Crinò, M. Tonato, I. Floriani, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer.

M. Rinaldi, L. Crinò, 2001, Lung cancer.

Identification of Targetable Driver Mutations In Molecularly Selected Never Smoker Lung Adenocarcinomas

L. Crinò, D. Aisner, R. Chiari, 2013 .

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

G. Scagliotti, S. Novello, L. Crinò, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Robustness of complex feedback systems: application to oncological biochemical networks

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2013, Int. J. Control.

Corrigendum to "Computational model of EGFR and IGF1R pathways in lung cancer: A Systems Biology approach for Translational Oncology" (Biotechnol Adv 30 (2012) 142-153)

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2013 .

Computational model of EGFR and IGF1R pathways in lung cancer: a Systems Biology approach for Translational Oncology.

Paolo Valigi, Fortunato Bianconi, Elisa Baldelli, 2012, Biotechnology advances.

Metastatic spindle cell carcinoma: a complete response induced by cisplatin and 5-fluorouracil.

L. Crinò, M. Tonato, M. Colozza, 1988, Anticancer research.

Radioresistant inhibition of lymphoma growth in congenitally athymic (nude) mice.

A. Goldin, L. Crinò, E. Bonmassar, 1977, Cancer research.

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

G. Giaccone, E. Petricoin, L. Crinò, 2021, Journal for ImmunoTherapy of Cancer.

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

S. Gettinger, E. Felip, L. Crinò, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

P-523 Phase II trial of BBR3464, a novel, bifunctional platinum analog, as second line treatment of non-small cell lung cancer patients

G. Scagliotti, S. Novello, L. Crinò, 2003 .

Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients

M. Varella‐Garcia, L. Crinò, R. Chiari, 2013, Cancer Chemotherapy and Pharmacology.

Development of new first-line therapeutic options for non-small-cell lung cancer.

L. Crinò, J. Foglietta, A. Hamzaj, 2006, Lung cancer.

Challenging problems in malignancy: case 1. Presentation of small-cell lung cancer with marked hyperamylasemia.

L. Crinò, S. Damiani, G. Benedetti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dyskerin and TERC expression may condition survival in lung cancer patients

L. Crinò, L. Montanaro, D. Treré, 2015, Oncotarget.

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

S. Gettinger, E. Felip, L. Crinò, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-coding RNAs in lung cancer

L. Crinò, G. Metro, B. Ricciuti, 2014, Oncoscience.

Long noncoding RNAs: new insights into non-small cell lung cancer biology, diagnosis and therapy

L. Crinò, R. Chiari, F. Paciullo, 2016, Medical Oncology.

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

Elisa Rossi, Vienna Ludovini, Lucio Crino, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.

A. Rossi, C. Gridelli, F. de Marinis, 2016, Clinical lung cancer.

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Role of liquid biopsy in oncogene-addicted non-small cell lung cancer.

L. Crinò, M. Canale, A. Delmonte, 2019, Translational lung cancer research.

Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program

E. Vasile, F. Cappuzzo, L. Crinò, 2018, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren’s syndrome

L. Crinò, V. Ludovini, R. Gerli, 2011, Lupus.

Plasma DNA, Microsatellite Alterations, and p53 Tumor Mutations Are Associated with Disease-Free Survival in Radically Resected Non-small Cell Lung Cancer Patients: A Study of the Perugia Multidisciplinary Team for Thoracic Oncology

L. Crinò, M. Tonato, I. Floriani, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance

L. Crinò, R. Chiari, F. Grignani, 2015, Ecancermedicalscience.

Inhibition of DNA methylation sensitizes glioblastoma for tumor necrosis factor-related apoptosis-inducing ligand-mediated destruction.

L. Ricci-Vitiani, R. Pallini, G. Stassi, 2005, Cancer research.

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

L. Crinò, F. Grignani, G. Leonardi, 2016, Expert review of respiratory medicine.

Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy

L. Crinò, A. Delmonte, G. Bronte, 2021, Expert review of anticancer therapy.

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

L. Landi, L. Crinò, M. Canale, 2020, Journal of clinical medicine.

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial

P. Jänne, A. Kohlmann, L. Crinò, 2017, JAMA.

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Lucio Crinò, Benjamin Solomon, Patrick Schnell, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

L. Crinò, A. Delmonte, G. Bronte, 2020, Frontiers in Oncology.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

L. Crinò, R. Chiari, C. Bennati, 2014, Clinical lung cancer.

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.

F. Cappuzzo, L. Crinò, G. Ceresoli, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Fortunato Bianconi, Elisa Baldelli, Vienna Ludovini, 2017, Oncotarget.

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidence

L. Crinò, M. Libra, C. Genova, 2019, OncoTargets and therapy.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

E. Felip, L. Crinò, E. Vokes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

Chun-Ming Tsai, Lucio Crinò, Karen Kelly, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of advanced non-small cell lung cancer.

G. Scagliotti, C. Gridelli, D. Galetta, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Yan Sun, Lucio Crino, Xiuyu Julie Cong, 2012, The Lancet. Oncology.

Diagnostic and prognostic potential of the proteomic profiling of serum-derived extracellular vesicles in prostate cancer

G. Muto, D. Bonci, A. Addario, 2021, Cell Death & Disease.

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

A. Chella, L. Landi, C. Tibaldi, 2014, British Journal of Cancer.

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

G. Giaccone, V. Torri, G. Scagliotti, 2003, Journal of the National Cancer Institute.

Second‐Line Treatment Options in Non–Small‐Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

N. Hanna, C. Gridelli, E. Felip, 2017, Clinical lung cancer.

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

G. Bepler, G. Scagliotti, F. de Marinis, 2003, Seminars in Oncology.

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer

L. Crinò, G. Martinelli, M. Canale, 2019, Journal of oncology.

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy

L. Crinò, M. Canale, A. Delmonte, 2022, Cancers.

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

L. Crinò, C. Ficorella, R. Chiari, 2019, Clinical and Translational Oncology.

Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy

L. Crinò, R. Chiari, G. Metro, 2017, Therapeutic advances in medical oncology.

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.

L. Crinò, R. Chiari, C. Bennati, 2012, Lung cancer.

Advances on EGFR mutation for lung cancer.

L. Crinò, G. Metro, 2012, Translational lung cancer research.

Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations

L. Crinò, F. Bianconi, R. Chiari, 2012, Cancer Chemotherapy and Pharmacology.

Targeted Therapies for Non-small-Cell Lung Cancer

L. Crinò, G. Metro, 2012 .

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

L. Crinò, G. Metro, 2011, Expert review of anticancer therapy.

Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?

F. Cappuzzo, L. Crinò, F. Blackhall, 2008, Targeted Oncology.

ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm.

A. Marchetti, F. Buttitta, F. Mucilli, 2017, JCO precision oncology.

Clinical impact of sequential treatment with ALK-TKIs in patients with advanced ALK-positive non-small cell lung cancer: Results of a multicenter analysis.

L. Crinò, A. Delmonte, R. Chiari, 2015, Lung cancer.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

Roman K. Thomas, F. Cappuzzo, E. Smit, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Malignant Giant Solitary Fibrous Tumor of the Pleura Metastatic to the Thyroid Gland

L. Crinò, R. Chiari, G. Leonardi, 2016, Tumori.

MYC and Human Telomerase Gene (TERC) Copy Number Gain in Early-stage Non–small Cell Lung Cancer

M. Varella‐Garcia, L. Crinò, V. Ludovini, 2015, American journal of clinical oncology.

Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.

P. Jänne, J. Engelman, S. Novello, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

F. Cappuzzo, F. Hirsch, M. Varella‐Garcia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice.

L. Crinò, M. Baretti, R. Chiari, 2016, Lung cancer.

Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.

L. Crinò, S. Bracarda, C. Caserta, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer

L. Crinò, M. Canale, E. Petracci, 2019, Journal of clinical medicine.

57 Cisplatin and etoposide followed by concurrent chemo-radiationtherapy for limited small cell lung cancer (SCLC-LD). The experience of two Italian institutions

F. Salvi, G. Frezza, L. Crinò, 2005 .

Epidermal Growth Factor Receptor Messenger RNA Expression, Gene Dosage, and Gefitinib Sensitivity in Non–Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006, Clinical Cancer Research.

A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.

L. Crinò, F. Puglisi, A. Paccagnella, 2010, Breast.

Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

F. Cappuzzo, A. Cancellieri, L. Crinò, 2004, Journal of the National Cancer Institute.

MicroRNA signature in metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies.

L. Landi, A. D’Incecco, G. Fontanini, 2014, Clinical colorectal cancer.

Epithelial‐to‐mesenchymal transition in the context of epidermal growth factor receptor inhibition in non‐small‐cell lung cancer

L. Crinò, A. Delmonte, G. Bronte, 2018, Biological reviews of the Cambridge Philosophical Society.

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma

C. Porta, M. Gore, L. Crinò, 2015, British Journal of Cancer.

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis: Track: Immunotherapy.

E. Felip, L. Crinò, N. Rizvi, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A randomized, double-blind phase 3 trial of adjuvant erlotinib (E) versus placebo (P) following complete tumor resection with or without adjuvant chemotherapy in patients (pts) with stage IB-IIIA EGFR positive (IHC/FISH) non-small cell lung cancer (NSCLC): RADIANT results.

Chun-Ming Tsai, Lucio Crino, Shaf Keshavjee, 2014 .

Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.

C. Gridelli, F. de Marinis, L. Crinò, 2008, Critical reviews in oncology/hematology.

Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.

P. Jänne, F. Cappuzzo, M. Varella‐Garcia, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy.

T. Mok, R. Salgia, E. Felip, 2017, Cancer treatment reviews.

Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series.

A. Marchetti, F. Buttitta, F. Cappuzzo, 2014, Clinical lung cancer.

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme

A. Marchetti, F. Buttitta, G. Scagliotti, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

P. Jänne, S. Ou, Gregory Riely, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.

L. Crinò, M. Papi, A. Ravaioli, 2013, Lung cancer.

Recommendations for the Analysis of ALK Gene Rearrangements in Non–Small-Cell Lung Cancer: A Consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology

A. Marchetti, G. Scagliotti, C. Gridelli, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

W. Franklin, M. Varella‐Garcia, R. Doebele, 2010, Clinical Cancer Research.

A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

L. Crinò, M. Tonato, F. Costanzo, 2008, Cancer Chemotherapy and Pharmacology.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical lung cancer.

Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors.

L. Crinò, M. Colozza, S. Gori, 2007, The oncologist.

Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.

F. Cappuzzo, F. Hirsch, E. Duffield, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New generation anaplastic lymphoma kinase inhibitors.

L. Crinò, G. Martinelli, A. Delmonte, 2019, Translational lung cancer research.

Optimal management of ALK-positive NSCLC progressing on crizotinib.

L. Crinò, R. Chiari, G. Metro, 2017, Lung cancer.

Future options for ALK-positive non-small cell lung cancer.

L. Crinò, R. Chiari, C. Bennati, 2015, Lung cancer.

Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.

L. Crinò, R. Chiari, C. Bennati, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC)

L. Crinò, R. Chiari, V. Ludovini, 2013, Virchows Archiv.

Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer.

G. Scagliotti, S. Novello, L. Crinò, 1999, Lung cancer.

Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer

G. Scagliotti, A. Ceribelli, S. Novello, 2005, British Journal of Cancer.

Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.

G. Scagliotti, M. Rinaldi, S. Novello, 2005, Lung cancer.

Induction therapy for early-stage non-small-cell lung cancer.

F. Cappuzzo, L. Crinò, S. Bartolini, 2004, Oncology.

Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.

F. Cappuzzo, F. de Marinis, L. Crinò, 2003, Lung cancer.

Emerging drugs for non-small cell lung cancer

F. Cappuzzo, L. Crinò, S. Bartolini, 2003, Expert opinion on emerging drugs.

Combined platinum containing treatment in NSCLC.

L. Crinò, 2002, Lung cancer.

Present and future treatment of advanced non-small cell lung cancer.

F. Cappuzzo, L. Crinò, 2002, Seminars in oncology.

Phase I II R andomized T rial C omparing T hree P latinum-Based Doublets i n A dvanced N on-Small-Cell L ung C ancer

G. Scagliotti, C. Gridelli, M. Rinaldi, 2002 .

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.

G. Scagliotti, C. Gridelli, M. Rinaldi, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

L. Crinò, V. Ludovini, M. Colozza, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Unveiling mutational dynamics in non‐small cell lung cancer patients by quantitative EGFR profiling in vesicular RNA

L. Crinò, A. Delmonte, E. Chiadini, 2021, Molecular oncology.

Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial

A. Chella, L. Landi, G. Alí, 2019, Clinical Cancer Research.

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience

L. Crinò, D. Calistri, M. Canale, 2021, Biomedicines.

Large Cell Neuroendocrine Carcinoma Transformation and EGFR‐T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR‐TKIs in Lung Cancer

L. Crinò, R. Chiari, V. Ludovini, 2017, Mayo Clinic proceedings.

The Evolving Role of Nivolumab in Non-Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

C. Gridelli, E. Felip, F. de Marinis, 2016, Clinical lung cancer.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine

E. Petricoin, M. Schabath, L. Crinò, 2015, PROTEOMICS - Clinical Applications.

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

A. Marchetti, F. Buttitta, A. Chella, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease

C. Dooms, A. Marchetti, L. Bubendorf, 2014 .

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.

S. Barni, G. Scagliotti, C. Gridelli, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM)

A. Marchetti, F. Cappuzzo, A. Rossi, 2019, Tumori.

Assessment of EGFR Mutations in Circulating Tumor Cell Preparations from NSCLC Patients by Next Generation Sequencing: Toward a Real-Time Liquid Biopsy for Treatment

A. Marchetti, F. Buttitta, A. Chella, 2014, PloS one.

Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

F. Cappuzzo, A. Cancellieri, L. Crinò, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.

F. Shepherd, L. Crinò, A. Sandler, 2000, Lung cancer.

Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.

S. Barni, C. Gridelli, F. de Marinis, 2011, Lung cancer.

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

G. Scagliotti, Serafino Pantano, C. Gridelli, 2017, The Lancet. Oncology.

Targeting EGFR and ALK in NSCLC: current evidence and future perspective.

L. Crinò, C. Bennati, A. Gili, 2016, Lung cancer management.

Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors

A. Marchetti, F. Mucilli, S. Novello, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

1183PDRISK STRATIFICATION MODEL FOR RESECTED SQUAMOUS CELL LUNG CANCER (R-SQLC) PATIENTS (PTS) ACCORDING TO CLINICAL AND PATHOLOGICAL FACTORS.

A. Marchetti, S. Novello, L. Crinò, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcome in Resected Non–Small Cell Lung Cancer Patients

L. Crinò, V. Ludovini, F. Bianconi, 2014, American journal of clinical oncology.

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

S Gori, L. Crinò, I. Floriani, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Cappuzzo, F. Shepherd, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR).

L. Crinò, D. Calistri, M. Canale, 2018, Journal of thoracic disease.

The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC

E. Smit, Yi-long Wu, M. Papotti, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

D. Ettinger, F. Cappuzzo, E. Smit, 2016, ESMO Open.

International Experts Panel Meeting of the Italian Association of Thoracic Oncology on Antiangiogenetic Drugs for Non–Small Cell Lung Cancer: Realities and Hopes

D. Lambrechts, C. Gridelli, E. Smit, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Therapeutic options targeting angiogenesis in nonsmall cell lung cancer

L. Crinò, G. Metro, 2014, European Respiratory Review.

Perspectives of Novel Imaging Techniques for Staging, Therapy Response Assessment, and Monitoring of Surveillance in Lung Cancer: Summary of the Dresden 2013 Post WCLC-IASLC State-of-the-Art Imaging Workshop

S. Schoenberg, C. Fink, P. Apfaltrer, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

74 Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC)

G. Scagliotti, L. Crinò, V. Adamo, 1997 .

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

L. Crinò, C. Sternberg, P. Marchetti, 2019, Clinical Cancer Research.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

E. Petricoin, L. Liotta, M. Schabath, 2015, Oncotarget.

Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer

P. Jänne, A. Shaw, L. Crinò, 2015, British Journal of Cancer.

Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.

Lucio Crinò, Vincenzo Minotti, L. Crinò, 2013, Future oncology.

P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain Metastases

L. Crinò, A. Delmonte, P. Ulivi, 2017 .

Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.

G. Peters, F. Shepherd, L. Crinò, 1998, Seminars in oncology.

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.

J. Nemunaitis, E. Felip, L. Crinò, 2015 .

Gemcitabine in non-small cell lung cancer

F. Cappuzzo, L. Crinò, 2002, Expert opinion on pharmacotherapy.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.

L. Crinò, M. Mottolese, F. Cognetti, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and

L. Crinò, M. Mottolese, F. Cognetti, 2010 .

2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

S Senan, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Consensus Conference on Lung Cancer : early-stage non-small-cell lung cancer consensus on diagnosis , treatment and follow-up

C. Dooms, G. Veronesi, R. Stahel, 2014 .

Preliminary results of a dose-finding study of paclitaxel and carboplatin in patients with advanced non-small cell lung cancer.

G. Scagliotti, L. Crinò, M. Tonato, 1996, Seminars in oncology.

Differences in the Availability of New Anti-Cancer Drugs for Italian Patients Treated in Different Regions. Results of Analysis Conducted by the Italian Society of Medical Oncology (AIOM)

P. Tagliaferri, L. Crinò, G. Beretta, 2010, Tumori.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

C. Schumann, M. Socinski, R. Kurek, 2015, The Lancet. Oncology.

Temozolomide-induced partial response in a patient with primary diffuse leptomeningeal gliomatosis

A. F. Marliani, L. Crinò, E. Franceschi, 2005, Journal of Neuro-Oncology.

Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2020 .

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

F. Cappuzzo, R. Trisolini, A. Cancellieri, 2006, Reviews on recent clinical trials.

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.

T. Mitsudomi, F. Shepherd, L. Crinò, 2016, The Lancet. Oncology.

Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors

L. Crinò, F. Spagnolli, E. Franceschi, 2006, Journal of Neuro-Oncology.

Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.

B. Barbiroli, L. Crinò, R. Lodi, 2003, Magnetic resonance imaging.

$sup 67$Ga scanning in the staging of Hodgkin's disease

L. Crinò, M. Tonato, M. Martelli, 1974 .

67Ga scanning in the staging of Hodgkin's disease.

L. Crinò, M. Tonato, M. Martelli, 1974, Acta haematologica.

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study

L. Crinò, S. Cascinu, S. Siena, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Kit Expression in Small Cell Carcinomas of the Lung: Effects of Chemotherapy

G. Rossi, L. Crinò, M. Migaldi, 2003, Modern Pathology.

Supportive Treatment in the Management of Lung Cancer

L. Crinò, 1999 .

107 Dose finding study of paclitaxel and carboplatin in previously untreated non small cell lung cancer

G. Scagliotti, L. Crinò, M. Tonato, 1997 .

Impaired growth of a radiation-induced lymphoma in intact or lethally irradiated allogeneic athymic (nude) mice.

A. Goldin, L. Crinò, E. Bonmassar, 1975, Transplantation.

Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.

L. Crinò, M. Reck, 2009, Lung cancer.

Epidermal Growth Factor Receptor Messenger RNAExpression , Gene Dosage , and Gefitinib Sensitivity in Non ^ Small Cell Lung Cancer

F. Cappuzzo, F. Hirsch, P. Bunn, 2006 .

Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)

P. Jänne, K. O'Byrne, Michael Thomas, 2012 .

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.

L. Crinò, P. Bruzzi, A. Ardizzoni, 1993, European journal of cancer.

9170 Safety and efficacy of first-line bevacizumab (Bv) plus chemotherapy in elderly patients (pts) with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): SAiL (MO19390)

N. Pavlakis, L. Crinò, N. Thatcher, 2009 .

Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer

F. Cappuzzo, L. Crinò, F. Mazzoni, 2004, British Journal of Cancer.

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

E. Petricoin, J. Carpten, L. Crinò, 2021, Genes.

Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (N

L. Crinò, I. Floriani, A. Paccagnella, 2012 .

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

L. Crinò, P. Bruzzi, F. Cognetti, 2008, Clinical breast cancer.

Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

A. Shaw, M. Ahn, L. Crinò, 2012 .

The Role of Histology with Common First-line Regimens for Advanced Non-small Cell Lung Cancer: A Brief Report of the Retrospective Analysis of a Three-arm Randomized Trial

G. Scagliotti, C. Gridelli, M. Rinaldi, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pemetrexed combination therapy in the treatment of non-small cell lung cancer.

L. Crinò, R. Rosell, 2002, Seminars in oncology.

Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).

S. Gettinger, L. Crinò, S. Ramalingam, 2016 .

Detection of EGFR Mutations in Plasma Cell-Free Tumor DNA of TKI-Treated Advanced-NSCLC Patients by Three Methodologies: Scorpion-ARMS, PNAClamp, and Digital PCR

L. Crinò, F. Roila, A. Delmonte, 2020, Diagnostics.

Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis.

E. Vasile, L. Crinò, L. Fioretto, 2011, Journal of the National Cancer Institute.

1207O Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial

C. Gridelli, L. Cavanna, L. Crinò, 2021, Annals of Oncology.

Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.

G. Scagliotti, S. Novello, L. Crinò, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

G. Giaccone, C. Gridelli, T. Mok, 2018, ESMO Open.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

M. Aristides, G. Scagliotti, C. Gridelli, 2005, Lung cancer.

Neo-adjuvant chemotherapy in early stages of non-small cell lung cancer.

L. Crinò, 2002, Lung cancer.

Postoperative Chemotherapy in Non-Small Cell Lung Cancer

S. Novello, L. Crinò, T. le Chevalier, 2000, Tumori.

Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous non-small cell lung cancer. The BEVERLY multicenter randomized phase III trial.

C. Gridelli, L. Cavanna, F. de Marinis, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer

G. Scagliotti, L. Crinò, M. Marangolo, 1996, Cancer Chemotherapy and Pharmacology.

Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer

D. Radisky, F. Modugno, P. Visca, 2014, Oncotarget.

Effects of Gefitinib on Serum Epidermal Growth Factor Receptor and HER2 in Patients with Advanced Non-Small Cell Lung Cancer

V. Torri, F. Cappuzzo, L. Crinò, 2004, Clinical Cancer Research.

Tumorlets, Multicentric Carcinoids, Lymph-Nodal Metastases, and Long-Term Behavior in Bronchial Carcinoids

L. Crinò, S. Ascani, R. Ribacchi, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer (NSCLC): Pooled analysis of two randomized trials.

R. Labianca, C. Tibaldi, E. Smit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biological Markers and DNA Flow Cytometric Analysis in Radically Resected Patients with Non-Small Cell Lung Cancer. A Study of the Perugia Multidisciplinary Team for Thoracic Tumors

L. Crinò, M. Tonato, I. Floriani, 2008, Tumori.

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

H. Groen, G. Scagliotti, H. Wakelee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)

H. Groen, E. Felip, L. Crinò, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase III comparative study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus docetaxel in patients with previously treated advanced or metastatic squamous cell non-small cell lung cancer (NSCLC).

M. Buyse, S. Gettinger, T. Lynch, 2013 .

Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib

L. Crinò, R. Chiari, C. Arcuri, 2018, Medical Oncology.

Clinical experience with gefitinib: an update.

F. Cappuzzo, R. Trisolini, A. Cancellieri, 2006, Critical reviews in oncology/hematology.

A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer (NSCLC) patients with KRAS mutations.

C. Schumann, S. Gettinger, Gregory Riely, 2012 .

Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

E. Scarpi, D. Amadori, L. Crinò, 2016, Clinical lung cancer.

OTT_A_177051 3171..3179

L. Crinò, M. Libra, C. Genova, 2019 .

Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

L. Crinò, M. Tonato, I. Floriani, 2017, BMC Cancer.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

C. Henschke, L. Crinò, F. Barlesi, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.

Lucio Crino, Roger B Cohen, P. Jänne, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)

L. Crinò, G. Ceresoli, S. Bartolini, 2004, British Journal of Cancer.

Gene Mutation Analysis in EGFR Wild Type NSCLC Responsive to Erlotinib: Are There Features to Guide Patient Selection?

Lucio Crinò, Dino Amadori, D. Amadori, 2014, International journal of molecular sciences.

A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.

G. Scagliotti, F. Cappuzzo, S. Novello, 2006, Lung cancer.

Alectinib’s activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series

L. Crinò, P. Floridi, R. Chiari, 2016, Journal of Neuro-Oncology.

Cyproterone acetate: hepatotoxicity and prostatic cancer treatment.

L. Crinò, G. Natalini, F. Roila, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.

D. Amadori, L. Crinò, D. Calistri, 2016 .

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)

Yi-long Wu, L. Crinò, Chun-Ming Tsai, 2017 .

Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study

G. Scagliotti, C. Gridelli, A. Shaw, 2016 .

A prospective study on survival in cancer patients with and without venous thromboembolism

R. Labianca, S. Gallus, C. Cimminiello, 2013, Internal and Emergency Medicine.

Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study.

S. Barni, F. Cappuzzo, S. Novello, 2015, Lung cancer.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

E. Petricoin, P. Valigi, L. Crinò, 2015, BMC systems biology.

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

L. Crinò, M. Tonato, M. Colozza, 2004, British Journal of Cancer.

Development of gemcitabine in non-small cell lung cancer: the Italian contribution.

L. Crinò, L. Toschi, G. Metro, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Treatment of advanced non-small cell lung cancer (NSCLC): the "Umbria" cooperative study.

L. Crinò, F. di Costanzo, E. Ballatori, 1988, Seminars in oncology.

OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC

S. Gettinger, L. Crinò, E. Vokes, 2019, Journal of Thoracic Oncology.

MA 10.06 Real-World Results in Non-Squamous Non-Small Cell Lung Cancer Patients: Italian Nivolumab Expanded Access Program

D. Galetta, L. Crinò, M. Tiseo, 2017 .

1301PDThree-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)

Burgio, S. Gettinger, L. Crinò, 2017 .

A Prospective Analysis of Chemotherapy Following Surgical Resection of Clinical Stage I‐II Small‐Cell Lung Cancer

L. Crinò, M. Tonato, P. Pelicci, 1993, American journal of clinical oncology.

Randomized, double-blind, phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor receptor-1 (IGF-1R), for advanced-stage non-small cell lung cancer (NSCLC).

J. Engelman, S. Novello, L. Crinò, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA‐bulky N2 and Stage IIIB nonsmall cell lung carcinoma

G. Scagliotti, F. Cappuzzo, S. Novello, 2003, Cancer.

B3-04: Gefitinib (IRESSA) versus vinorelbine in chemonaïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study

F. Hirsch, E. Duffield, A. Armour, 2007 .

miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy.

L. Landi, F. Cappuzzo, L. Crinò, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intramedullary spinal metastasis from ovarian cancer.

L. Crinò, F. Calbucci, L. di Tommaso, 2005, The Lancet Oncology.

A phase II study of RAD001 (R) (everolimus) monotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing prior platinum-based chemotherapy (C) or prior C and EGFR inhibitors (EGFR-I)

G. Giaccone, F. Cappuzzo, F. Shepherd, 2007 .

MA16.11 CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials

P. Jänne, T. Mitsudomi, M. Ahn, 2017 .

Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.

G. Rossi, L. Crinò, G. Martinelli, 2020, Lung cancer.

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.

C. Henschke, L. Crinò, F. Barlesi, 2012 .

Italian cohort of nivolumab Expanded Access Programme (EAP): Preliminary data from a real-world population.

G. Minuti, D. Galetta, L. Crinò, 2016 .

Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (MRCC) – Final Results

C. Porta, M. Gore, L. Crinò, 2012 .

Whole body and intracranial efficacy of ceritinib in patients (pts) with crizotinib (CRZ) pretreated, ALK‐rearranged (ALK+) non‐small cell lung cancer (NSCLC) and baseline brain metastases (BM): Results from ASCEND‐1 and ASCEND‐2 trials: 141PD

G. Scagliotti, A. Shaw, T. Mok, 2016, Journal of Thoracic Oncology.

215TiP: STELLAR - A phase II trial of TTFields with chemotherapy for first line treatment of malignant mesothelioma.

A. Chella, L. Crinò, U. Weinberg, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Combined modality therapy for stage IIIA (clinical N2) non-small cell carcinoma of the lung (NSCLC)

L. Crinò, M. Tonato, E. Maranzano, 1991 .

Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life (QOL) in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, R. Salgia, K. Wilner, 2012 .

Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC).

G. Scagliotti, C. Gridelli, S. Novello, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line Bevacizumab-Based Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer

C. Gridelli, L. Crinò, R. Passalacqua, 2012, Clinical Drug Investigation.

Medical treatment of brain metastases from solid tumours.

L. Crinò, F. Mazzoni, C. Calandri, 2000, Forum.

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

F. Cappuzzo, L. Crinò, S. Bartolini, 2003, British Journal of Cancer.

9168 Safety and efficacy of first-line bevacizumab-based therapy in advanced non-small cell lung cancer (NSCLC): results of the SAiL study (MO19390)

N. Pavlakis, Yi-long Wu, L. Crinò, 2009 .

Targeting angiogenesis in advanced non-small-cell lung cancer: are biomarkers needed?

L. Crinò, G. Metro, M. Cenci, 2013, Current Respiratory Care Reports.

Adjuvant erlotinib (E) versus placebo (P) in non-small cell lung cancer (NSCLC) patients (pts) with tumors carrying EGFR-sensitizing mutations from the RADIANT trial.

N. Altorki, K. Kelly, E. Cho, 2014 .

Improved efficacy of gefitinib therapy in phospho-Akt positive patients with advanced non-small cell lung cancer.

L. Crinò, G. Ceresoli, V. Ludovini, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

INCREASED BONE PAIN AFTER SUSPENSION OF BUSERELIN TREATMENT IN DISSEMINATED PROSTATIC CANCER

L. Crinò, F. Roila, G. Pasquarella, 1988, The Lancet.

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer.

C. Dooms, A. Marchetti, K. Syrigos, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.

C. Dooms, A. Marchetti, L. Bubendorf, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Epithelial-to-mesenchymal transition and EGFR status in NSCLC: the role of vimentin expression.

L. Crinò, G. Bronte, S. Bravaccini, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease.

P Baas, C. Dooms, A. Marchetti, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390)

H. Groen, E. Felip, L. Crinò, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

E. Petricoin, P. Valigi, L. Crinò, 2015, BMC Systems Biology.

Presentation of Nonseminomatous Germ Cell Tumor of the Testis with Symptomatic Solitary Bone Metastasis. A Case Report with Review of the Literature

L. Crinò, P. Castellucci, S. Damiani, 2006, Tumori.

Combination chemotherapy with gemcitabine in non-small-cell lung cancer

L. Crinò, 1997 .

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies ( NP 28673 1 and NP 28761 ) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer

Jie Yang, R. Govindan, A. Shaw, 2017 .

Cisplatin, etoposide, and mitomycin in the treatment of non‐small cell carcinoma of the lung. A pilot study

L. Crinò, M. Colozza, F. Grignani, 1986, Cancer.

HER2, EGFR, PIK3CA mutations in HER2+ metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T): Incidence and correlation with response

L. Crinò, V. Ludovini, M. Colozza, 2008 .

Postsurgical follow-up is always necessary in bronchial carcinoid.

L. Crinò, Niccolò Daddi, F. Puma, 2014, The Annals of thoracic surgery.

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

N. Altorki, K. Kelly, E. Cho, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

L. Crinò, G. Bronte, C. Magri, 2023, International journal of molecular sciences.

MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).

L. Crinò, C. Zhou, M. Reck, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.

L. Crinò, M. Tonato, A. Mosconi, 1997, Seminars in oncology.

Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

E. Smit, L. Crinò, M. Boyer, 2008 .

hMENA splicing program impacts the clinical outcome of early stage lung cancer patients. How and why?

P. Visca, L. Crinò, V. Ludovini, 2014, Journal of Translational Medicine.

Gemcitabine in Advanced Pancreatic Cancer: A Phase II Trial

L. Crinò, M. Tonato, E. Corgna, 1997, American journal of clinical oncology.

Temozolomide (TMZ) for progressive primitive brain tumors: safety at 75 mg/m2 a day for 21 days every 28: A GICNO (Italian Neuro-Oncology Group) study

L. Crinò, M. Ermani, E. Franceschi, 2005 .

Optimal management of ALK-positive NSCLC progressing on crizotinib.

L. Crinò, R. Chiari, G. Metro, 2017, Lung cancer.

Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).

L. Crinò, M. Clerici, M. Tonato, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

L. Landi, C. Tibaldi, A. D’Incecco, 2014, Clinical lung cancer.

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

D. Ruysscher, E. Felip, L. Crinò, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Superiority of three-drug combination chemotherapy versus cisplatin-etoposide in advanced non-small cell lung cancer: a randomized trial by the Italian Oncology Group for Clinical Research.

L. Crinò, M. Clerici, F. di Costanzo, 1995, Lung Cancer.

E. Petricoin, M. Schabath, L. Crinò, 2015, Proteomics. Clinical applications.

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

W. Franklin, R. Doebele, L. Crinò, 2010, Clinical Cancer Research.

A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Efficacy results (NCT01086826).

L. Crinò, I. Floriani, A. Paccagnella, 2013 .

Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.

L. Crinò, C. Calandri, A. Maestri, 2001, Oncology.

Müllerian Tumor Originating from the Pleura in a 47-Years Old Woman: A Case Report

L. Crinò, R. Chiari, S. Gori, 2016 .

Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

L. Crinò, I. Floriani, V. Ludovini, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

How to discriminate non-small cell lung cancer (NSCLC) cases from an Italian administrative database? A retrospective, secondary data use study for evaluating a novel algorithm performance

L. Crinò, A. Delmonte, I. Massa, 2021, BMJ Open.

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

G. Giaccone, F. Shepherd, L. Crinò, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Non-small cell lung cancer, early stage

L. Bubendorf, T. Yamanaka, M. Okada, 2012 .